🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kinarus AG (Basel CH) has signed a Transaction Agreement with Perfect Holding SA (SIX:PRFN) anticipating the acquisition of Kinarus and enabling listing of Kinarus on the SIX Swiss Exchange. Ventac Partners served as exclusive corporate advisor. kinarus.com/images/Press/2…

Today's elevator pitch session concludes the 18th edition of our week-long “Build a Biotech” course @NTNUnorway Teams of bioscience and entrepreneurship students did excellent work developing 10 bio/medtech cases into viable and investment-worthy businesses. #Entrepreneurship

We are proud to announce that Lars Hedbys, a partner at Ventac Partners and CEO of RhoVac AB , has completed an acquisition of a Danish oncology company Chosa ApS. RhoVac AB has now changed its name to Chosa Oncology AB news.cision.com/rhovac/r/rhova…

We are delighted to see our portfolio company, RORA Biologics, complete its exclusive license agreement with Case Western Reserve University Case Western Reserve for cancer and HIV therapy technologies developed by its Chief Scientific Officer Dr. Rafick Sékaly. thedaily.case.edu/case-western-r…

New publication from our portfolio co. Regenesance BV (dba Complement Pharma BV) with Alexion in the J. of Innate Immunity - validation of new humanized C6 MAb inhibiting assembly of the membrane attack complex (MAC): karger.com/Article/Pdf/52…

Today marks the start of the 20th edition of Ventac Partners “build a biotech” course at NTNU. 80+ Master's & PhD students will spend the week learning about IP strategy & product development, and work in groups to turn 10 technology cases into investable businesses.

Friday 24th March saw the final day of our week-long “build a biotech” course at @NTNUnorway with some entertaining and successful elevator pitches to some skeptical investors. This was the biggest class since the course started in 2004 and in terms of performance, the best!

Our portfolio company, Cenexum Technologies, has entered a worldwide, exclusive license with Aarhus University covering a bio-electronics platform technology targeting next-generation neuromodulation solutions. Aarhus University also becomes a shareholder in Cenexum.

Our Partner, Robert L. Buchanan, has been accepted for admission to the bar of the Supreme Court of the United States via nomination by his alma mater Suffolk University Law School . There will be a swearing in ceremony and reception at the Court next year. Congratulations Bob!

Ventac portfolio co. Orbit Genomics (early warning genomics for disease diagnosis) named a Deep Tech Pioneer by Hello Tomorrow out of an astonishing 4,500 applications from 120 countries. Meet Orbit at the Hello Tomorrow Global Summit, March 2024 hello-tomorrow.org/global-summit/…

As 2023 draws to a close, the entire Ventac Partners team extends our warmest wishes for the holiday season. May 2024 bring you success and new opportunities.

Congratulations to our portfolio company Orbit Genomics, selected for the inaugural cohort of startups in CancerX’s Accelerator program: orbitgenomics.com/2024/02/26/orb…

As mentioned here three months ago, our Partner, Robert L. Buchanan, was accepted for admission to the Bar of the Supreme Court of the United States (SCOTUS). Bob duly attended the swearing in ceremony and reception at SCOTUS on Friday of last week. Congratulations again Bob!

Friday 15th March concluded our “build a biotech” course NTNU in Norway, with successful elevator pitches to initially skeptical investors. This was the 21st edition and as usual the teams did excellent work in converting our 10 technology cases into investable business cases.

Our portfolio company Cenexum Technologies will be presenting its innovative platform for diagnosing and treating neurological diseases - with a first product for accurately detecting epileptic seizures - at the Nordic Innovation Fair in Copenhagen on 24/09 #nordicinnovationfair

Our portfolio company Orbit Genomics has been awarded 2M USD in SBIR America's Seed Fund funding from the NIH and National Cancer Institute - a Phase II SBIR Grant to develop its OrbiSeq™-L subtyping lung cancer diagnostic test for patients with indeterminate pulmonary nodules. Congratulations to the team!

Our partner Dede Willis is presenting the Porth Distinguished Lecture today at Missouri S&T : “From Lab to Market: Commercializing University Life Science Innovations" calendar.mst.edu/event/dede-wil…

Encouraging news from our portfolio company Cenexum, a spin-out from Aarhus University, which has been awarded an Innofounder Grant from the Innovation Fund Denmark Innovationsfonden : linkedin.com/posts/cenexum-…

Wishing all of our clients, industry colleagues and their families a joyous holiday season and a prosperous New Year filled with success and exciting opportunities! Warmly, The Ventac Partners Team

We are expanding in Australasia 🚀with new partners Kieran Elborough, NZ & Andrew Venables, AU. Their 30+ yrs experience each in science R&D, finance & biotech boosts our #LifeSciences advisory & company building capabilities. Welcome! #CompanyBuilding #StrategicAdvisory